CN108699107B - Cftr调节剂及其使用方法 - Google Patents

Cftr调节剂及其使用方法 Download PDF

Info

Publication number
CN108699107B
CN108699107B CN201680082474.2A CN201680082474A CN108699107B CN 108699107 B CN108699107 B CN 108699107B CN 201680082474 A CN201680082474 A CN 201680082474A CN 108699107 B CN108699107 B CN 108699107B
Authority
CN
China
Prior art keywords
substituted
unsubstituted
nhc
nhnr
halogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680082474.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN108699107A (zh
Inventor
A·韦尔科曼
M·H·莱温
O·希尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California San Diego UCSD
Original Assignee
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California San Diego UCSD filed Critical University of California San Diego UCSD
Publication of CN108699107A publication Critical patent/CN108699107A/zh
Application granted granted Critical
Publication of CN108699107B publication Critical patent/CN108699107B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Prostheses (AREA)
  • Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
CN201680082474.2A 2015-12-24 2016-12-23 Cftr调节剂及其使用方法 Active CN108699107B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562387591P 2015-12-24 2015-12-24
US62/387,591 2015-12-24
PCT/US2016/068561 WO2017112947A1 (en) 2015-12-24 2016-12-23 Cftr regulators and methods of use thereof

Publications (2)

Publication Number Publication Date
CN108699107A CN108699107A (zh) 2018-10-23
CN108699107B true CN108699107B (zh) 2022-05-10

Family

ID=59091233

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680082474.2A Active CN108699107B (zh) 2015-12-24 2016-12-23 Cftr调节剂及其使用方法

Country Status (15)

Country Link
US (2) US20190031630A1 (OSRAM)
EP (1) EP3394083B9 (OSRAM)
JP (1) JP6894902B2 (OSRAM)
KR (1) KR102723194B1 (OSRAM)
CN (1) CN108699107B (OSRAM)
AU (2) AU2016377782B2 (OSRAM)
CL (1) CL2018001714A1 (OSRAM)
CO (1) CO2018007239A2 (OSRAM)
ES (1) ES2901002T3 (OSRAM)
IL (2) IL299924B2 (OSRAM)
PL (1) PL3394083T3 (OSRAM)
PT (1) PT3394083T (OSRAM)
RU (1) RU2742934C2 (OSRAM)
WO (1) WO2017112947A1 (OSRAM)
ZA (1) ZA201804228B (OSRAM)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3066112T3 (en) 2015-12-24 2026-05-11 The Regents Of The Univ Of California Cftr regulators and methods of use thereof
IT201700085714A1 (it) * 2017-07-26 2019-01-26 Luigi Maiuri Approccio terapeutico per il trattamento e/o prevenzione di condizioni di sensibilità al glutine.
EP3672598A4 (en) * 2017-08-24 2021-04-28 The Regents of The University of California OCULAR PHARMACEUTICAL COMPOSITIONS
FR3096890B1 (fr) * 2019-06-07 2021-05-14 H4 Orphan Pharma Utilisation d’une molécule opioïde pour traiter l’œil sec et l’œil allergique.
US20220071549A1 (en) * 2020-09-08 2022-03-10 The Regents Of The University Of California Apparatus, systems and methods of use for ocular surface potential difference measurement
PY2193067A (es) 2020-10-23 2022-06-20 Ildong Pharmaceutical Co Ltd Compuestos moduladores del cftr, composiciones y usos de estos
CN113527225B (zh) * 2021-07-15 2022-11-18 南昌大学 一种丙烯酰噻二唑衍生物及其制备方法和应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005075435A1 (en) * 2004-01-30 2005-08-18 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
WO2010073011A2 (en) * 2008-12-23 2010-07-01 Betagenon Ab Compounds useful as medicaments
WO2012092471A2 (en) * 2010-12-29 2012-07-05 Development Center For Biotechnology Novel tubulin inhibitors and methods of using the same
WO2015138909A1 (en) * 2014-03-13 2015-09-17 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing cftr activity

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1917999A (en) 1998-03-31 1999-10-18 Warner-Lambert Company Quinoxalinones as serine protease inhibitors such as factor xa and thrombin
AP2005003292A0 (en) * 2002-09-30 2005-06-30 Univ California Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof
US7977322B2 (en) 2004-08-20 2011-07-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US20090105240A1 (en) * 2007-10-17 2009-04-23 Tomas Mustelin Methods for treating leukemia and myelodysplastic syndrome, and methods for identifying agents for treating same
AU2009221327B2 (en) 2008-03-05 2014-03-27 Merck Patent Gmbh Quinoxalinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes
US8314239B2 (en) 2008-10-23 2012-11-20 Vertex Pharmaceutical Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
EP3157917B1 (en) 2014-06-19 2020-03-18 Proteostasis Therapeutics, Inc. Compounds, compositions and methods of increasing cftr activity

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005075435A1 (en) * 2004-01-30 2005-08-18 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
WO2010073011A2 (en) * 2008-12-23 2010-07-01 Betagenon Ab Compounds useful as medicaments
WO2012092471A2 (en) * 2010-12-29 2012-07-05 Development Center For Biotechnology Novel tubulin inhibitors and methods of using the same
WO2015138909A1 (en) * 2014-03-13 2015-09-17 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing cftr activity

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
A High Throughput Assay for Discovery of Bacterial-Glucuronidase Inhibitors;Syed Ahmad et al;《Current Chemical Genomics》;20110408;第5卷;第13-20页 *
Diverse Small Molecule Inhibitors of Human Apurinic/Apyrimidinic Endonuclease APE1 Identified from a Screen of a Large Public Collection;Dorjbal Dorjsuren et al;《PLOS ONE》;20121031;第7卷(第10期);e47974（1-12页） *
Small-molecule CFTR activators increase tear secretion and prevent experimental dry eye disease;Alyssa M. Flores et al;《The FASEB Journal》;20160531;第30卷;第1789-1797页 *

Also Published As

Publication number Publication date
RU2742934C2 (ru) 2021-02-11
ES2901002T3 (es) 2022-03-21
RU2018126959A (ru) 2020-01-24
PL3394083T3 (pl) 2022-01-17
PT3394083T (pt) 2021-12-07
CO2018007239A2 (es) 2018-07-19
JP6894902B2 (ja) 2021-06-30
NZ743720A (en) 2024-08-30
EP3394083B1 (en) 2021-09-01
CN108699107A (zh) 2018-10-23
CA3009531A1 (en) 2017-06-29
US20200140402A1 (en) 2020-05-07
WO2017112947A1 (en) 2017-06-29
AU2021257948A1 (en) 2021-11-25
AU2016377782B2 (en) 2021-07-29
KR20180101415A (ko) 2018-09-12
RU2018126959A3 (OSRAM) 2020-08-20
CL2018001714A1 (es) 2018-10-26
IL260210A (en) 2018-07-31
AU2016377782A1 (en) 2018-07-12
ES2901002T9 (es) 2022-06-20
AU2021257948B2 (en) 2023-11-30
IL260210B2 (en) 2023-06-01
IL299924B1 (en) 2024-09-01
EP3394083B9 (en) 2022-04-27
IL299924A (en) 2023-03-01
EP3394083A4 (en) 2019-09-04
US20190031630A1 (en) 2019-01-31
BR112018012927A2 (en) 2018-12-11
ZA201804228B (en) 2020-09-30
EP3394083A1 (en) 2018-10-31
IL299924B2 (en) 2025-01-01
US11192869B2 (en) 2021-12-07
JP2018538354A (ja) 2018-12-27
KR102723194B1 (ko) 2024-10-28

Similar Documents

Publication Publication Date Title
US11192869B2 (en) CFTR regulators and methods of use thereof
US12065412B2 (en) CFTR regulators and methods of use thereof
US12503447B2 (en) CFTR regulators and methods of use thereof
CA3009531C (en) 5-substituted [1,3,4]thiadiazol-2-amido derivatives and use as cftr reg ulators

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant